GSK is paying $500M upfront for rights to a series of Hengrui drugs, the latest case of a pharma company looking to a Chinese firm to build out its pipeline.

Coalition for Health AI wants to help with using AI to implement work requirements for Medicaid. Experts say that's difficult ...

Initial analyses of the Trump administration’s proposed NIH cuts neglect key aspects of their long-term economic and health ...

For over an hour, Jeff Vierstra lay still in Columbia University’s ALS clinic, as a doctor poked him ankle-to-throat with an ...

With Covid vaccines, New York state chose a “let 'er rip” public health policy rather than more stringent enforcement of ...

Millions of older Americans living in poverty are entitled to free or heavily subsidized Medicare coverage. But the new ...

President Trump is threatening to withhold funds from supervised drug consumption sites and potentially pursue criminal ...

HCA Healthcare and Tenet Healthcare, for-profit chains that collectively own 240 hospitals, both said their revenue and ...

Morning. Today, we discuss how Duchenne patients and their families are responding to the shelving of Sarepta Therapeutics’ ...

President Trump wants to end homelessness in America. His plan? Make it easier to involuntarily treat people with serious ...

European regulators on Friday said that the Duchenne muscular dystrophy gene therapy Elevidys should not be approved ...

European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.